One of the most common types is the BRAF V600E mutation. The name V600E describes the nature and location of the mutation: V and E represent the amino acids (building blocks of protein) that mutated.

V600E is a mutation of the BRAF gene in which valine (V) is substituted by glutamic acid (E) at amino acid 600.

Apr 16, 2024 · In this review, we cover the current understanding of BRAF mutations and associated clinical characteristics in patients with metastatic NSCLC, approved and emerging treatment options, BRAF...

View Therapies for BRAF V600E BRAF V600E is a predictive biomarker for use of dabrafenib, vemurafenib, trametinib, encorafenib, cetuximab, cobimetinib, panitumumab, binimetinib, cemiplimab, imatinib, and pembrolizumab in patients.

Jul 21, 2022 · FDA previously approved the dabrafenib–trametinib combination for the treatment of people with advanced forms of specific cancers whose tumors have the BRAF V600E mutation, including non-small cell lung cancer, melanoma, and anaplastic thyroid cancer.

Jan 22, 2025 · There are different mutations within BRAF, but the one with FDA-approved treatments in lung cancer is BRAF V600E. This mutation is a specific variation in the BRAF protein. How do you know if you have a BRAF-positive lung cancer?

One such mutation in papillary thyroid cancer is the BRAF V600E mutation which has been observed in 27-87% of all papillary thyroid cancers. The present study examines whether the BRAF V600E mutation is associated with more aggressive papillary thyroid cancer.

4 days ago · Background: Encorafenib + cetuximab (EC) is approved for previously treated BRAF V600E-mutant metastatic colorectal cancer (mCRC) based on the BEACON phase 3 study (NCT02928224). Historically, first-line (1L) treatment of BRAF V600E-mutant mCRC with chemotherapy (chemo) regimens has had limited efficacy.BREAKWATER (NCT04607421) is an open-label, global, randomized, phase 3 study evaluating 1L ...

5 days ago · BRAF mutations occur in approximately 8-12% of cases and are associated with aggressive tumor growth, low efficacy from SOC treatments and a poor prognosis, with a median overall survival less than 12 months. Previously, there were no first-line targeted therapies approved for patients with BRAF V600E-mutant mCRC.

Apr 16, 2024 · In this review, we cover the current understanding of BRAF mutations and associated clinical characteristics in patients with metastatic NSCLC, approved and emerging treatment options, BRAF sequencing approaches, and unmet needs. The BRAF V600E mutation confers constitutive activity of the …